stalling on tirzepatide Most stalls aren’t the GLP-1 failing. They’re a dose schedule built for a study, not for you, plus four metabolic roadblocks nobody checked. , Save this before your next dose increase‼️, ———, #reels 4-week stall on 7.5 mg

To elucidate the molecular mechanisms by which tirzepatide, a GIPR/GLP-1R dualagonist, and peptide 20, a GIPR/GLP-1R/GCGR triagonist, manifest their superior efficacies over monoagonist such as semaglutide, we determined cryo-electron microscopy structures of tirzepatide-bound GIPR and GLP-1R as well as peptide 20-bound GIPR, GLP-1R and GCGR The structures reveal both common and unique features for the dual and triple agonism by illustrating key interactions of clinical relevance at the atomic level

Starting at a low dose and titrating slowly helps minimize these effects

doi: 10.1016/j.jamda.2017.05.026 59

so they are not PGN

SGLT2 Inhibitors: Heart and Kidney Protection: why these medicines matter beyond HbA1c

The delayed gastric emptying effect of exenatide may affect the absorption of oral medications